Cargando…

Plasma Big Endothelin-1 Level Predicted 5-Year Major Adverse Cardiovascular Events in Patients With Coronary Artery Ectasia

Background: Coronary artery ectasia (CAE) is found in about 1% of coronary angiography and is associated with poor clinical outcomes. The prognostic value of plasma big Endothelin-1 (ET-1) in CAE remains unknown. Methods: Patients with angiographically confirmed CAE from 2009 to 2015, who had big ET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Zhongxing, Wang, Haoyu, Yuan, Sheng, Yin, Dong, Song, Weihua, Dou, Kefei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667227/ https://www.ncbi.nlm.nih.gov/pubmed/34912865 http://dx.doi.org/10.3389/fcvm.2021.768431

Ejemplares similares

Development and Validation of a Nomogram for Predicting the Risk of Adverse Cardiovascular Events in Patients with Coronary Artery Ectasia
por: Cai, Zhongxing, et al.
Publicado: (2021)

Effect of type 2 diabetes on coronary artery ectasia: smaller lesion diameter and shorter lesion length but similar adverse cardiovascular events
por: Cai, Zhongxing, et al.
Publicado: (2022)

Predictive Value of Plasma Big Endothelin-1 in Adverse Events of Patients With Coronary Artery Restenosis and Diabetes Mellitus: Beyond Traditional and Angiographic Risk Factors
por: Ma, Yue, et al.
Publicado: (2022)

Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease
por: Dregoesc, Mihaela Ioana, et al.
Publicado: (2022)

Plasma Big Endothelin-1 Levels and Long-Term Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
por: Lyu, Si-qi, et al.
Publicado: (2022)

Independent Prognostic Value of High-sensitivity C-reactive Protein in Patients with Coronary Artery Ectasia
por: Wang, Yintang, et al.
Publicado: (2016)

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial
por: Ma, Teng, et al.
Publicado: (2023)

CT-Based Leiden Score Outperforms Confirm Score in Predicting Major Adverse Cardiovascular Events for Diabetic Patients with Suspected Coronary Artery Disease
por: Liu, Zinuan, et al.
Publicado: (2022)

Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
por: Okkonen, Marjo, et al.
Publicado: (2021)

Directly Measured vs. Calculated Low-Density Lipoprotein Cholesterol Does Not Identify Additional Individuals With Coronary Artery Disease and Diabetes at Higher Risk of Adverse Events: Insight From a Large Percutaneous Coronary Intervention Cohort in Asia
por: Shi, Boqun, et al.
Publicado: (2022)

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial
por: Zheng, Jianan, et al.
Publicado: (2023)

Development and Validation of a Nomogram of In-hospital Major Adverse Cardiovascular and Cerebrovascular Events in Patients With Acute Coronary Syndrome
por: Bo, Xiangwei, et al.
Publicado: (2021)

Risk factors for major adverse cardiovascular events after coronary artery bypass grafting using radial artery grafts
por: Xia, Tianyu, et al.
Publicado: (2023)

The relationship between elevated magnesium levels and coronary artery ectasia
por: Mustafa, Yolcu, et al.
Publicado: (2016)

Prognostic value of N-terminal Pro–B-Type natriuretic peptide in patients with intermediate coronary lesions
por: Song, Chenxi, et al.
Publicado: (2022)

Prediabetes as a risk factor for major adverse cardiovascular events
por: Mando, Ramy, et al.
Publicado: (2021)

microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation
por: de los Reyes-García, Ascensión M., et al.
Publicado: (2023)

The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention
por: Giantini, Astuti, et al.
Publicado: (2023)

Editorial: Advances in predicting future adverse coronary events: the role of cardiovascular imaging and coronary physiology indices
por: Seitun, Sara, et al.
Publicado: (2023)

Elevated Plasma Big Endothelin-1 at Admission Is Associated With Poor Short-Term Outcomes in Patients With Acute Decompensated Heart Failure
por: Mo, Ran, et al.
Publicado: (2021)

Comparison of conventional scoring systems to machine learning models for the prediction of major adverse cardiovascular events in patients undergoing coronary computed tomography angiography
por: Ghorashi, Seyyed Mojtaba, et al.
Publicado: (2022)

Risk prediction model for major adverse cardiovascular events (MACE) during hospitalization in patients with coronary heart disease based on myocardial energy metabolic substrate
por: Na, Li, et al.
Publicado: (2023)

Five-years’ prognostic analysis for coronary artery ectasia patients with coronary atherosclerosis: A retrospective cohort study
por: Liu, Ruifeng, et al.
Publicado: (2022)

Coronary artery calcium score on standard of care oncologic CT scans for the prediction of adverse cardiovascular events in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Koutroumpakis, Efstratios, et al.
Publicado: (2022)

Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
por: Muñoz-Bravo, Carlos, et al.
Publicado: (2023)

Estimation of Major Adverse Cardiovascular Events in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Risk Prediction Score Model From a Derivation and Validation Study
por: Zhao, Xiaoxiao, et al.
Publicado: (2020)

Serum YKL-40 in coronary heart disease: linkage with inflammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events
por: Song, Mowei, et al.
Publicado: (2023)

Treatment and Outcome of Patients With Coronary Artery Ectasia: Current Evidence and Novel Opportunities for an Old Dilemma
por: Esposito, Luca, et al.
Publicado: (2022)

Is Coronary Artery Ectasia a Progressive Disease? A Self-Controlled Retrospective Cohort Study
por: Liu, Ruifeng, et al.
Publicado: (2021)

Prediction of major adverse cardiovascular events in patients with acute coronary syndrome: Development and validation of a non-invasive nomogram model based on autonomic nervous system assessment
por: Wang, Jun, et al.
Publicado: (2022)

Association of Big Endothelin-1 with Coronary Artery Calcification
por: Qing, Ping, et al.
Publicado: (2015)

Association Between Circulating Retinol-Binding Protein 4 and Adverse Cardiovascular Events in Stable Coronary Artery Disease
por: Qian, Ke, et al.
Publicado: (2022)

Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials
por: Deng, Chang-Jiang, et al.
Publicado: (2023)

Leukocyte Telomere Length Shortening Implies Plaque Instability and Major Adverse Cardiovascular Events in Patients With Angiographically Intermediate Lesions
por: Zhang, Alian, et al.
Publicado: (2022)

Novel Insight Into Long-Term Risk of Major Adverse Cardiovascular and Cerebrovascular Events Following Lower Extremity Arteriosclerosis Obliterans
por: Sun, Ji, et al.
Publicado: (2022)

A prediction model for major adverse cardiovascular events in patients with heart failure based on high-throughput echocardiographic data
por: Sun, Qinliang, et al.
Publicado: (2022)

Prediction models for major adverse cardiovascular events following ST-segment elevation myocardial infarction and subgroup-specific performance
por: Chen, Weiyao, et al.
Publicado: (2023)

The Usefulness of C-Reactive Protein to Albumin Ratio in the Prediction of Adverse Cardiovascular Events in Coronary Chronic Total Occlusion Undergoing Percutaneous Coronary Intervention
por: Cheng, Lele, et al.
Publicado: (2021)

Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
por: Shi, Haiming, et al.
Publicado: (2022)

Invasive and anticoagulant treatment for coronary ectasia: a single operator’s experience in a tertiary hospital in South Africa
por: Grigorov, V
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ndbqtftnevat380r7jvt4mld2e